Luo Yuxi, Song Guiqin, Liang Shichu, Li Feifei, Liu Kang
Institute of Tissue Engineering and Stem Cells, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China.
The First Clinic of Anhui Medical University, Hefei, Anhui 230032, P.R. China.
Exp Ther Med. 2021 May;21(5):484. doi: 10.3892/etm.2021.9915. Epub 2021 Mar 16.
Chimeric antigen receptor (CAR)-modified T-cells are T-cells that have been genetically engineered to express CAR molecules to target specific surface antigens on tumor cells. CAR T-cell therapy, a novel cancer immunotherapy, has been attracting increasing attention, since it exhibited notable efficacy in the treatment of hematological tumors in clinical trials. However, for this type of therapy, challenges must be overcome in the treatment of solid tumors. Furthermore, certain side effects associated with CAR T-cell therapy, including cytokine release syndrome, immune effector cell-related neurotoxicity syndrome, tumor lysis syndrome and on-target off-tumor toxicity, must be taken into consideration. The present study provides a systematic review of the principle, clinical application, current challenges, possible solutions and future perspectives for CAR T-cell therapy.
嵌合抗原受体（CAR）修饰的T细胞是经过基因工程改造以表达CAR分子的T细胞，这些CAR分子可靶向肿瘤细胞上的特定表面抗原。CAR-T细胞疗法是一种新型癌症免疫疗法，自其在临床试验中对血液系统肿瘤的治疗显示出显著疗效以来，一直备受关注。然而，对于这类疗法，在实体瘤治疗中必须克服诸多挑战。此外，还必须考虑到与CAR-T细胞疗法相关的某些副作用，包括细胞因子释放综合征、免疫效应细胞相关神经毒性综合征、肿瘤溶解综合征和靶向非肿瘤毒性。本研究对CAR-T细胞疗法的原理、临床应用、当前挑战、可能的解决方案及未来前景进行了系统综述。
